Efficiency of Bumetanide in Autistic Children

• Status: Completed
• Trial end date: 2011-06-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if a treatment by bumetanide presents an efficiency at the level of the neuronal maturation in the autism

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Hospital, Brest
• Treatments: Bumetanide

Criteria

Inclusion Criteria:

• Children from 3 to 10 years old, answering the diagnosis of typical autism according to the diagnostic criteria of autism of the classification of the WHO ( CIM-10) and the parents of which gave a free, enlightened and written consent.

Exclusion Criteria:

• Patients epileptic autistics treated by anticomitiaux or having hurts of the central nervous system

• Patients autistics receiving a psychotropic treatment

• Patients presenting disorders electrolytes

• Patients presenting a hypersensibility known about sulpha drugs

• Presenting patients against indications relative to the treatment by bumetanide

• Patients already treated by diuretics

• Patients presenting a hepatic or renal incapacity

• Patients presenting an elongation of the QT to the electrocardiogram.

• Patients autistics of CARS sore is lower than 30.